OPINION | This article contains opinion. This site is licensed to publish this content.
The Food and Drug Administration issued warnings to Americans that received the Johnson & Johnson COVID-19 vaccine, according to The Western Journal.
“Reports of adverse events following use of the Janssen COVID-19 Vaccine under emergency use authorization suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination,” the FDA stated.
NEW: The FDA warns that J&J's coronavirus vaccine can increase the risk of Guillain-Barré syndrome. Risk is low but 3-5 times > than in general population. The neurological disorder was also linked to the 1976 swine flu vaccine. @SharonLNYT @noahweiland https://t.co/4B4WhASEmO
— Sheryl Gay Stolberg (@SherylNYT) July 12, 2021
The J&J #Covid vaccine may be linked to a small increased risk of developing Guillain-Barré syndrome, @US_FDA says. With the EMA saying last week that AstraZeneca's vaccine may also trigger GBS, people will be looking to see if there's a class effect. https://t.co/RLZdaNxeZ5
— Helen Branswell (@HelenBranswell) July 12, 2021
FDA Will Announce Rare Incidence Of Guillain-Barre Linked To Johnson & Johnson Vaccine via @forbes https://t.co/3dLnSH0G4a
— Dr. Nina L. Shapiro (@drninashapiro) July 12, 2021
Symptoms will include “weakness or tingling sensations, especially in the legs or arms; difficulty walking or with facial movements; and difficulty with bladder control or bowel functions,” writes The Western Journal.
100 cases of Guillain-Barré have been reported according to the CDC.
“Guillain Barré syndrome (a neurological disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who have received the Janssen COVID-19 Vaccine.”
“In most of these people, symptoms began within 42 days following receipt of the Janssen COVID-19 Vaccine. “
From The Western Journal:
Existing evidence “is insufficient to establish a causal relationship,” the FDA said, according to The Post.
The FDA said it “continues to find the known and potential benefits clearly outweigh the known and potential risks” of the Johnson & Johnson vaccine.
In its reporting, The New York Times said that incidence of the rare nerve disorder “appear to be three to five times higher among recipients of the Johnson & Johnson vaccine than among the general population in the United States.”
The FDA said symptoms of having Guillain-Barré include weakness or tingling sensations, especially in the legs or arms; difficulty walking or with facial movements; and difficulty with bladder control or bowel functions.
Most of those affected have been men aged 50 and older, according to the CDC.
